Macrophage‐specific and systemic inhibition of Runx1 effectively blocks MMT‐driven tumor formation in vivo, representing a druggable therapeutic target to eliminate tumor‐promoting CAFs in NSCLC patients. This evidence concerns the gene RUNX1 and neoplasm.